GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lineage Cell Therapeutics Inc (XTAE:LCTX) » Definitions » Cash Receipts from Securities Related Activities

Lineage Cell Therapeutics (XTAE:LCTX) Cash Receipts from Securities Related Activities


View and export this data going back to 2015. Start your Free Trial

What is Lineage Cell Therapeutics Cash Receipts from Securities Related Activities?

Cash Receipts from Securities Related Activities only applicable to companies reporting Cash Flow from Operations in direct method.


Lineage Cell Therapeutics (XTAE:LCTX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lineage Cell Therapeutics Inc (XTAE:LCTX) » Definitions » Cash Receipts from Securities Related Activities
Traded in Other Exchanges
Address
2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cell transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.